Alemtuzumab
DB00087
Approved Indication
Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
11
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.
Details
DrugBank ID
DB00087 ↗
Approval Date
2009-11-30
Molecular Weight
— g/mol
Drug Class
Other
ATC Codes
L04AA34
Synonyms
—
ChEMBL
CHEMBL1201587 ↗
Drug References (DrugBank)